Daily low-dose oral etoposide for recurrent epithelial ovarian cancer after platinum-based therapy.
The activity and toxicity of oral etoposide in women with recurrent ovarian cancer are described from a case series of women who had measurable disease. All patients had had previous platinum-based chemotherapy. Etoposide was given as 50 mg/day for 21 days every 4 weeks until there was progression of the disease or prohibitive toxicity. Twelve patients were enrolled into this study. Ten patients received a total of 48 cycles of etoposide; the median number of cycles was 4 (range 1-11). There were two partial responses (20%; 95% CI, 0-45%). The responses lasted 3.5 and 6 months. Median progression-free interval (PFI) was 7.5 months (range 5.5-11), and median survival time was 8.5 months (range 1.2-21.5). The main haematological toxicity was leukopenia and no treatment-related death occurred. Although etoposide appears to exhibit activity in recurrent ovarian cancer, response and survival durations are short, with a high rate of complications.
Moosavi
A S
AS
Department of Gynecology Oncology, Valli-e-Asr Hospital, Tehran University of Medical Sciences, Iran. a3064@sina.tums.ac.ir
Gilani
M M
MM
Tehranian
A
A
Esfahani
J K
JK
D002288:Adenocarcinoma, Mucinous / Q000188:drug therapy / Q000401:mortality / Q000473:pathology; D000284:Administration, Oral; D000328:Adult; D000368:Aged; D018283:Cystadenocarcinoma, Papillary / Q000188:drug therapy / Q000401:mortality / Q000473:pathology; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007492:Iran; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D011446:Prospective Studies; D016019:Survival Analysis; D017211:Treatment Failure
D005047:Etoposide